Role of Lipid Metabolism Reprogramming in the Progression and Drug Resistance of Ovarian Cancer

doi:10.12280/gjfckx.20250573

Abstract

Abstract:

Ovarian cancer is a gynecological malignant tumor with the highest mortality rate, and its recurrence and drug resistance are closely related to lipid metabolism reprogramming. Studies have shown that abnormal lipid metabolism promotes the synthesis of fatty acid and cholesterol through the abnormal activation of core metabolic enzymes, alters the fluidity of the cell membrane, and drives oncogenic signal transduction. Meanwhile, ascites, exosomes, and immune cells in the tumor microenvironment further enhance tumor metastasis and platinum resistance through lipid transport and metabolic remodeling. Moreover, lipid metabolism interacts with epigenetic modifications and immune checkpoint regulation to reshape the immune response and induce immune escape. These mechanisms work together to maintain the survival, invasion, and drug-resistant phenotypes of cancer cells. Therefore, targeting the key nodes or related pathways of lipid metabolism is not only expected to become molecular markers for the diagnosis and prognosis of ovarian cancer, but also provides a theoretical basis for the combined treatment strategy of metabolic intervention and immune regulation, showing important clinical translational value.

Key words: Ovarian neoplasms, Lipid metabolism, Tumor microenvironment, Drug resistance, Phenotype

QIN Chen, ZHANG Wei, LI Li. Role of Lipid Metabolism Reprogramming in the Progression and Drug Resistance of Ovarian Cancer[J]. Journal of International Obstetrics and Gynecology, 2025, 52(5): 492-497.

References 30

[1]	Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3):229-263. doi: 10.3322/caac.21834.
[2]	Criscuolo D, Avolio R, Calice G, et al. Cholesterol Homeostasis Modulates Platinum Sensitivity in Human Ovarian Cancer[J]. Cells, 2020, 9(4):828. doi: 10.3390/cells9040828.
[3]	Kopecka J, Trouillas P, Gašparović AČ, et al. Phospholipids and cholesterol: Inducers of cancer multidrug resistance and therapeutic targets[J]. Drug Resist Updat, 2020, 49:100670. doi: 10.1016/j.drup.2019.100670.
[4]	Tan Y, Li J, Zhao G, et al. Metabolic reprogramming from glycolysis to fatty acid uptake and beta-oxidation in platinum-resistant cancer cells[J]. Nat Commun, 2022, 13(1):4554. doi: 10.1038/s41467-022-32101-w. pmid: 35931676
[5]	Pavlova NN, Thompson CB. The Emerging Hallmarks of Cancer Metabolism[J]. Cell Metab, 2016, 23(1):27-47. doi: 10.1016/j.cmet.2015.12.006. pmid: 26771115
[6]	Martínez-Reyes I, Chandel NS. Cancer metabolism: looking forward[J]. Nat Rev Cancer, 2021, 21(10):669-680. doi: 10.1038/s41568-021-00378-6. pmid: 34272515
[7]	Bian X, Liu R, Meng Y, et al. Lipid metabolism and cancer[J]. J Exp Med, 2021, 218(1):e20201606. doi: 10.1084/jem.20201606.
[8]	Ji Z, Shen Y, Feng X, et al. Deregulation of Lipid Metabolism: The Critical Factors in Ovarian Cancer[J]. Front Oncol, 2020, 10:593017. doi: 10.3389/fonc.2020.593017.
[9]	Wang Y, Wang Y, Shen L, et al. Prognostic and therapeutic implications of increased ATP citrate lyase expression in human epithelial ovarian cancer[J]. Oncol Rep, 2012, 27(4):1156-1162.doi: 10.3892/or.2012.1638. pmid: 22266777
[10]	Wojnarowicz PM, Breznan A, Arcand SL, et al. Construction of a chromosome 17 transcriptome in serous ovarian cancer identifies differentially expressed genes[J]. Int J Gynecol Cancer, 2008, 18(5):963-975. doi: 10.1111/j.1525-1438.2007.01134.x.
[11]	Palazzolo S, Saorin G, Corona G, et al. A carrier free delivery system of a MAGL inhibitor is effective on ovarian cancer[J]. Eur J Pharm Biopharm, 2024, 203:114397. doi: 10.1016/j.ejpb.2024.114397.
[12]	Wang Y, Hu M, Cao J, et al. ACSL4 and polyunsaturated lipids support metastatic extravasation and colonization[J]. Cell, 2025, 188(2):412-429.e27. doi: 10.1016/j.cell.2024.10.047. pmid: 39591965
[13]	Wu R, Li N, Huang W, et al. Melittin suppresses ovarian cancer growth by regulating SREBP1-mediated lipid metabolism[J]. Phytomedicine, 2025, 137:156367. doi: 10.1016/j.phymed.2025.156367.
[14]	Wu Y, Jia C, Liu W, et al. Sodium citrate targeting Ca²⁺/CAMKK2 pathway exhibits anti-tumor activity through inducing apoptosis and ferroptosis in ovarian cancer[J]. J Adv Res, 2024, 65:89-104. doi: 10.1016/j.jare.2024.04.033.
[15]	Wang H, Luo S, Yin Y, et al. DLAT is involved in ovarian cancer progression by modulating lipid metabolism through the JAK2/STAT5A/SREBP1 signaling pathway[J]. Cancer Cell Int, 2025, 25(1):25. doi: 10.1186/s12935-025-03656-7. pmid: 39871246
[16]	Chen RR, Yung M, Xuan Y, et al. Targeting of lipid metabolism with a metabolic inhibitor cocktail eradicates peritoneal metastases in ovarian cancer cells[J]. Commun Biol, 2019, 2:281. doi: 10.1038/s42003-019-0508-1. pmid: 31372520
[17]	Zhang J, Liu H, Wu Q, et al. Exosomal ANXA2 facilitates ovarian cancer peritoneal metastasis by activating peritoneal mesothelial cells through binding with TLR2[J]. Cell Commun Signal, 2024, 22(1):616. doi: 10.1186/s12964-024-01987-y. pmid: 39709496
[18]	Luo H, She X, Zhang Y, et al. PLIN2 Promotes Lipid Accumulation in Ascites-Associated Macrophages and Ovarian Cancer Progression by HIF1α/SPP1 Signaling[J]. Adv Sci(Weinh), 2025, 12(12):e2411314. doi: 10.1002/advs.202411314.
[19]	Mukherjee A, Chiang CY, Daifotis HA, et al. Adipocyte-Induced FABP4 Expression in Ovarian Cancer Cells Promotes Metastasis and Mediates Carboplatin Resistance[J]. Cancer Res, 2020, 80(8):1748-1761. doi: 10.1158/0008-5472.CAN-19-1999. pmid: 32054768
[20]	Kouba S, Ouldamer L, Garcia C, et al. Lipid metabolism and Calcium signaling in epithelial ovarian cancer[J]. Cell Calcium, 2019, 81:38-50. doi: 10.1016/j.ceca.2019.06.002. pmid: 31200184
[21]	Tang R, Zhu Y, Chen L, et al. Lipid metabolites abnormally expressed in pelvic fluid as potential biomarkers for ovarian cancer: A case-control study[J]. J Proteomics, 2024, 307:105261. doi: 10.1016/j.jprot.2024.105261.
[22]	Feng J, Rouse CD, Taylor L, et al. Regulation of Age-Related Lipid Metabolism in Ovarian Cancer[J]. Int J Mol Sci, 2025, 26(1):320. doi: 10.3390/ijms26010320.
[23]	Lin F, Li X, Wang X, et al. Stanniocalcin 1 promotes metastasis, lipid metabolism and cisplatin chemoresistance via the FOXC2/ITGB6 signaling axis in ovarian cancer[J]. J Exp Clin Cancer Res, 2022, 41(1):129. doi: 10.1186/s13046-022-02315-3. pmid: 35392966
[24]	Xuan Y, Wang H, Yung MM, et al. SCD1/FADS2 fatty acid desaturases equipoise lipid metabolic activity and redox-driven ferroptosis in ascites-derived ovarian cancer cells[J]. Theranostics, 2022, 12(7):3534-3552. doi: 10.7150/thno.70194. pmid: 35547771
[25]	Su YT, Chang WC, Chen L, et al. Ether-Linked Glycerophospholipids Are Potential Chemo-Desensitisers and Are Associated With Overall Survival in Carcinoma Patients[J]. J Cell Mol Med, 2024, 28(24):e70277. doi: 10.1111/jcmm.70277.
[26]	Yi J, Wu M, Zheng Z, et al. Integrated analysis of DNA methylome and transcriptome reveals SFRP1 and LIPG as potential drivers of ovarian cancer metastasis[J]. J Gynecol Oncol, 2023, 34(6):e71. doi: 10.3802/jgo.2023.34.e71. pmid: 37417299
[27]	Gu H, Bock C, Mikkelsen TS, et al. Genome-scale DNA methylation mapping of clinical samples at single-nucleotide resolution[J]. Nat Methods, 2010, 7(2):133-136. doi: 10.1038/nmeth.1414. pmid: 20062050
[28]	Sutton MN, Glazer SE, Al Zaki A, et al. Statins inhibit onco-dimerization of the 4Ig isoform of B7-H3[J]. bioRxiv,2024 Dec 20:2024.12.18.628944. doi: 10.1101/2024.12.18.628944.
[29]	Hwang SM, Awasthi D, Jeong J, et al. Transgelin 2 guards T cell lipid metabolism and antitumour function[J]. Nature, 2024, 635(8040):1010-1018. doi: 10.1038/s41586-024-08071-y.
[30]	Yin ZY, He SM, Zhang XY, et al. Apolipoprotein B100 acts as a tumor suppressor in ovarian cancer via lipid/ER stress axis-induced blockade of autophagy[J]. Acta Pharmacol Sin, 2025, 46(5):1445-1461. doi: 10.1038/s41401-024-01470-x.